McDermott, John H.

Dr. McDermott, John H.


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
ASAna Sergijenko
Ana Sergijenko
ALAlexander Langford-Smith
Alexander Langford-Smith
ALAi Y Liao
Ai Y Liao
CPClaire E Pickford
Claire E Pickford
MHMcDermott, John H.
McDermott, John H.
Brian BiggerBrian Bigger
Brian Bigger
Mucopolysaccharidosis type IIIA (MPSIIIA) is a lysosomal storage disorder caused by mutations in N-sulfoglucosamine sulfohydrolase (SGSH), resulting in heparan sulfate (HS) accumulation and progressive neurodegeneration. There are no treatments. We previously demonstrated improved neuropathology in MPSIIIA mice using lentiviral vectors (LVs) overexpressing SGSH in wild-type (WT) hematopoietic stem cell (HSC) transplants (HSCTs), achieved via donor monocyte/microglial engraftment in the brain. However, neurological disease was not corrected using LVs in autologous MPSIIIA HSCTs. To improve brain expression via monocyte/microglial specificity, LVs expressing enhanced green fluorescent protein (eGFP) under ubiquitous phosphoglycerate kinase (PGK) or myeloid-specific promoters were compared in transplanted HSCs. LV-CD11b-GFP gave significantly higher monocyte/B-cell eGFP expression than LV-PGK-GFP or LV-CD18-GFP after 6 months. Subsequently, autologous MPSIIIA HSCs were transduced with either LV-PGK-coSGSH or LV-CD11b-coSGSH vectors expressing codon-optimized SGSH and transplanted into MPSIIIA mice. Eight months after HSCT, LV-PGK-coSGSH vectors produced bone marrow SGSH (576% normal activity) similar to LV-CD11b-coSGSH (473%), but LV-CD11b-coSGSH had significantly higher brain expression (11 versus 7%), demonstrating improved brain specificity. LV-CD11b-coSGSH normalized MPSIIIA behavior, brain HS, GM2 ganglioside, and neuroinflammation to WT levels, whereas LV-PGK-coSGSH partly corrected neuropathology but not behavior. We demonstrate compelling evidence of neurological disease correction using autologous myeloid driven lentiviral-HSC gene therapy in MPSIIIA mice.

22 October 2019 in Brain
Verified
Journal Article
Open access
FVFrédéric M Vaz
Frédéric M Vaz
MHMcDermott, John H.
McDermott, John H.
MAMariëlle Alders
Mariëlle Alders
SWSaskia B Wortmann
Saskia B Wortmann
SKStefan Kölker
Stefan Kölker
SBSiddharth Banka
Siddharth Banka
CTP:phosphoethanolamine cytidylyltransferase (ET), encoded by PCYT2, is the rate-limiting enzyme for phosphatidylethanolamine synthesis via the CDP-ethanolamine pathway. Phosphatidylethanolamine is one of the most abundant membrane lipids and is particularly enriched in the brain. We identified five individuals with biallelic PCYT2 variants clinically characterized by global developmental delay with regression, spastic para- or tetraparesis, epilepsy and progressive cerebral and cerebellar atrophy. Using patient fibroblasts we demonstrated that these variants are hypomorphic, result in altered but residual ET protein levels and concomitant reduced enzyme activity without affecting mRNA levels. The significantly better survival of hypomorphic CRISPR-Cas9 generated pcyt2 zebrafish knockout compared to a complete knockout, in conjunction with previously described data on the Pcyt2 mouse model, indicates that complete loss of ET function may be incompatible with life in vertebrates. Lipidomic analysis revealed profound lipid abnormalities in patient fibroblasts impacting both neutral etherlipid and etherphospholipid metabolism. Plasma lipidomics studies also identified changes in etherlipids that have the potential to be used as biomarkers for ET deficiency. In conclusion, our data establish PCYT2 as a disease gene for a new complex hereditary spastic paraplegia and confirm that etherlipid homeostasis is important for the development and function of the brain.

21 March 2022 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
MHMcDermott, John H.
McDermott, John H.
AMAjit Mahaveer
Ajit Mahaveer
RJRachel A. James
Rachel A. James
NBNicola Booth
Nicola Booth
MTMark Turner
Mark Turner
KEKath Eaton
Kath Eaton
Aminoglycoside antibiotics are commonly used worldwide to treat gram-negative infections. They have proven efficacy and their safety profile is well recognized.1 In high doses, or with protracted regimens, aminoglycosides cause nephrotoxicity and ototoxicity, the latter of which can manifest as either vestibulotoxicity or cochleotoxicity.2 It was noted in the latter part of the 20th century that certain families have a predisposition to aminoglycoside-induced ototoxicity (AIO), whereby a single dose could cause profound and irreversible hearing loss.3,4

27 November 2017 in Brain
Verified
Journal Article
Open access
PDF file
RHRebecca J Holley
Rebecca J Holley
SEStuart M Ellison
Stuart M Ellison
DFDaniel Fil
Daniel Fil
COClaire O’leary
Claire O’leary
MHMcDermott, John H.
McDermott, John H.
Brian BiggerBrian Bigger
Brian Bigger
Mucopolysaccharidosis IIIB is a paediatric lysosomal storage disease caused by deficiency of the enzyme α-N-acetylglucosaminidase (NAGLU), involved in the degradation of the glycosaminoglycan heparan sulphate. Absence of NAGLU leads to accumulation of partially degraded heparan sulphate within lysosomes and the extracellular matrix, giving rise to severe CNS degeneration with progressive cognitive impairment and behavioural problems. There are no therapies. Haematopoietic stem cell transplant shows great efficacy in the related disease mucopolysaccharidosis I, where donor-derived monocytes can transmigrate into the brain following bone marrow engraftment, secrete the missing enzyme and cross-correct neighbouring cells. However, little neurological correction is achieved in patients with mucopolysaccharidosis IIIB. We have therefore developed an ex vivo haematopoietic stem cell gene therapy approach in a mouse model of mucopolysaccharidosis IIIB, using a high-titre lentiviral vector and the myeloid-specific CD11b promoter, driving the expression of NAGLU (LV.NAGLU). To understand the mechanism of correction we also compared this with a poorly secreted version of NAGLU containing a C-terminal fusion to IGFII (LV.NAGLU-IGFII). Mucopolysaccharidosis IIIB haematopoietic stem cells were transduced with vector, transplanted into myeloablated mucopolysaccharidosis IIIB mice and compared at 8 months of age with mice receiving a wild-type transplant. As the disease is characterized by increased inflammation, we also tested the anti-inflammatory steroidal agent prednisolone alone, or in combination with LV.NAGLU, to understand the importance of inflammation on behaviour. NAGLU enzyme was substantially increased in the brain of LV.NAGLU and LV.NAGLU-IGFII-treated mice, with little expression in wild-type bone marrow transplanted mice. LV.NAGLU treatment led to behavioural correction, normalization of heparan sulphate and sulphation patterning, reduced inflammatory cytokine expression and correction of astrocytosis, microgliosis and lysosomal compartment size throughout the brain. The addition of prednisolone improved inflammatory aspects further. Substantial correction of lysosomal storage in neurons and astrocytes was also achieved in LV.NAGLU-IGFII-treated mice, despite limited enzyme secretion from engrafted macrophages in the brain. Interestingly both wild-type bone marrow transplant and prednisolone treatment alone corrected behaviour, despite having little effect on brain neuropathology. This was attributed to a decrease in peripheral inflammatory cytokines. Here we show significant neurological disease correction is achieved using haematopoietic stem cell gene therapy, suggesting this therapy alone or in combination with anti-inflammatories may improve neurological function in patients.

21 January 2019 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
DSDeciphering Developmental Disorders (DDD) Study
Deciphering Developmental Disorders (DDD) Study
MZMarkus Zweier
Markus Zweier
ABAnaïs Begemann
Anaïs Begemann
KMKirsty McWalter
Kirsty McWalter
MCMegan T. Cho
Megan T. Cho
ARAnita Rauch
Anita Rauch

1 August 2017 in Cell Systems
Verified
Journal Article
Closed access
JKJong Wook Kim
Jong Wook Kim
OAOmar O. Abudayyeh
Omar O. Abudayyeh
HYHuwate Yeerna
Huwate Yeerna
CYChen-Hsiang Yeang
Chen-Hsiang Yeang
MSMichelle Stewart
Michelle Stewart
PTPablo Tamayo
Pablo Tamayo